Omburtamab, identified by the CAS number 1895083-75-6, represents an new therapeutic entity currently under testing development. This antibody, designed as neutralize the PD-1 receptor, shows significant capability in combating various neoplastic diseases. Present findings demonstrate that Omburtamab, working by body's regulation reduction, is a… Read More

Murlentamab GM102: The Innovative Therapeutic in Research Development Murulentamab GM102 represents an innovative method for addressing relapsed numerous cancers . This humanized targeted molecule specifically targets BCMA antigen expressed on cancerous cells, stimulating antibody-dependent cellular killing. Early clinical findi… Read More